Biological Dynamics' ExoVita Pancreas
Biological Dynamics said this week that it has validated and launched a laboratory-developed test, ExoVita Pancreas, through the company's CLIA-certified and CAP-accredited lab. The firm's assay platform involves isolation of exosomes with particular protein biomarkers from a standard blood sample, in this case to detect stage 1 and stage 2 pancreatic ductal adenoma carcinomas.
Biological Dynamics said that it intends to further validate the assay in a trial called ExoLuminate, which is currently enrolling patients with a high risk for pancreatic cancer. Eligible patients include those with a known familial or genetic predisposition, or certain clinical symptoms.